AXT Inc vs Celestica Inc — how do they compare? AXT Inc trades at $51.46 (market cap $3.77B), while Celestica Inc trades at $329.65 (market cap $39.28B). The key difference: Celestica Inc is far larger — about 10.4× AXT Inc's market cap, and Celestica Inc is trading nearer its 52-week high, AXT Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | CLS | |
|---|---|---|
Market Cap | $3.77B | $39.28B |
Sector | Technology | Technology |
52-Week High | $140.83 | $472.40 |
52-Week Low | $1.92 | $156.91 |
Enterprise Value | $3.73B | $39.68B |
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $50.46, down 11.8% in the past 24 hours, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improved margins. Recent news highlights strong AI-driven demand for indium phosphide substrates and a $100M+ backlog, but export delays and cash flow risks remain concerns. Analyst consensus is bullish with 7 buy ratings, but technical indicators suggest near-term pressure.
The stock faces near-term headwinds from weak cash flow and high valuations (P/S 27.84), but long-term growth potential exists if AI demand materializes and capacity expansion executes smoothly. Key risks include geopolitical tensions affecting exports and execution challenges in scaling production. Investors should weigh the bullish analyst outlook against persistent fundamental weaknesses and technical bearishness.
Celestica (CLS) trades at $345.18, down 4.08% over 24 hours, with technical indicators showing a bearish trend near key support at $339. The company demonstrates strong fundamentals with Q1 2026 EPS of $2.16 beating estimates, revenue growth accelerating to 55.55% YoY, and a robust ROE of 52.45%. Recent leadership appointments and raised FY2026 revenue guidance to $19 billion reflect operational momentum amid AI and data center demand tailwinds.
Wall Street maintains a bullish outlook with 63% buy ratings and a $440.10 consensus price target, implying 27% upside. Key risks include competitive pressures in the EMS sector and execution challenges in margin expansion. The stock's high P/E of 41.82 warrants monitoring, but earnings beats and institutional confidence support a positive investment case pending Q2 results on July 28, 2026.
Trailing returns across standard periods
Latest headlines on both assets
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →